Potassium binder may help heart failure patients stay on lifesaving drugs

NCT ID NCT07576257

Not yet recruiting Disease control Sponsor: Sahlgrenska University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a potassium binder called Sodium Zirconium Cyclosilicate can help heart failure patients take higher, more effective doses of a standard medication (aldosterone receptor antagonist) without dangerous potassium spikes. About 110 adults over 70 with heart failure and reduced kidney function will participate. The trial has two phases: an initial open-label period to adjust doses, followed by a 6-month blinded comparison against placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sodium Zirconium Cyclosilicate (a potassium binder)
What this could lead to: If successful, this could help more heart failure patients tolerate higher doses of aldosterone receptor antagonists, potentially improving heart function and reducing hospitalizations.
What could go wrong: This is a small, early-phase trial (Phase 2) with only 110 participants, so results may not apply broadly. The potassium binder itself can cause side effects like stomach upset or electrolyte imbalances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

More trials for these conditions

Other studies related to the condition(s) this trial covers.